Turning Point Brands (TPB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
The 2026 Annual Meeting will be held virtually on May 4, 2026, with stockholders able to participate and vote online using a unique control number.
Stockholders will vote on electing ten directors, ratifying KPMG LLP as the independent auditor, and approving executive compensation on an advisory basis.
Proxy materials, including the annual report, are available online, and multiple voting methods are provided for convenience.
Voting matters and shareholder proposals
Proposals include: election of ten directors for one-year terms, ratification of KPMG LLP as auditor, and a non-binding say-on-pay vote for executive compensation.
The Board recommends voting FOR all director nominees, FOR auditor ratification, and FOR executive compensation approval.
Stockholders may submit proposals for the 2027 meeting by November 25, 2026, following SEC and bylaw requirements.
Board of directors and corporate governance
The Board consists of ten members with diverse backgrounds and skills, including a majority who self-identify as women or people of color.
Board leadership separates the CEO and Executive Chairman roles, with a Lead Independent Director ensuring independent oversight.
Three standing committees: Audit, Compensation, and Nominating & Governance, all composed of independent directors.
Directors receive annual cash retainers and RSUs; committee chairs and the Lead Independent Director receive additional compensation.
Corporate governance guidelines, code of ethics, and insider trading policies are in place.
Latest events from Turning Point Brands
- Modern Oral net sales jumped 266%, driving 29% overall revenue growth and strong 2026 outlook.TPB
Q4 20252 Mar 2026 - Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 20242 Feb 2026 - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 202415 Jan 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor change, officer liability limits, and executive pay approval.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025